Achieving and maintaining long-term optimal improvements in patient-reported symptoms, signs, and quality of life among patients with moderate-to-severe psoriasis treated with guselkumab: 5-year data from VOYAGE 1

被引：0
|
作者：
Griffiths, Christopher E. M. [1 ]
Blauvelt, Andrew [2 ]
Han, Chenglong [3 ]
Fernandez-Penas, Pablo [4 ,5 ]
Adam, David N. [6 ,7 ]
Philipp, Sandra [8 ]
Song, Michael [9 ]
Miller, Megan [9 ]
You, Yin [9 ]
Langley, Richard G. [10 ]
机构：
[1] Univ Manchester, Salford Royal NHS Fdn Trust, NIHR Manchester Biomed Res Ctr, Dermatol Ctr, Manchester, Lancs, England
[2] Oregon Med Res Ctr, Portland, OR USA
[3] Janssen Global Serv LLC, Raritan, NJ USA
[4] Univ Sydney, Sydney, NSW, Australia
[5] Westmead Hosp, Westmead, NSW, Australia
[6] CCA Med Res Corp & Probity Med Res, Ajax, ON, Canada
[7] Prob Med Res, Waterloo, ON, Canada
[8] Charite Univ Med Berlin, Dept Dermatol, Berlin, Germany
[9] Janssen Res & Dev LLC, Raritan, NJ USA
[10] Dalhousie Univ, Halifax, NS, Canada
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2021年 / 85卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
27043
引用
收藏
页码：AB127 / AB127
页数：1
相关论文
共 50 条
  • [1] Maintaining long-term improvements in patient-reported symptoms, signs, and quality of life among patients with moderate to severe plaque psoriasis treated with guselkumab: VOYAGE 2, 5-year data
    Armstrong, April W.
    Gordon, Kenneth B.
    Spelman, Lynda
    Papp, Kim A.
    Han, Chenglong
    Song, Michael
    You, Yin
    Puig, Luis
    Ferris, Laura K.
    Reich, Kristian
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB167 - AB167
  • [2] Achieving and maintaining long-term optimal improvements in patient-reported symptoms, signs, and quality of life among patients with moderate to severe psoriasis treated with guselkumab: 3-year data from VOYAGE 1
    Blauvelt, Andrew
    Han, Chenglong
    Papp, Kim A.
    Griffiths, Christopher E. M.
    Fernandez-Penas, Pablo
    Adam, David N.
    Philipp, Sandra
    Song, Michael
    Shen, Yaung-Kaung
    Kimball, Alexa B.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB165 - AB165
  • [3] Achieving and maintaining long-term optimal improvements in patient-reported symptoms, signs, and quality of life among patients with moderate to severe psoriasis treated with guselkumab: 3-year data from VOYAGE 1
    Blauvelt, A.
    Han, C.
    Papp, K. A.
    Griffiths, C. E.
    Fernandez-Penas, P.
    Adam, D. N.
    Philipp, S.
    Song, M.
    Shen, Y. -K.
    Kimball, A. B.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 49 - 49
  • [4] Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial
    Papp, K. A.
    Blauvelt, A.
    Kimball, A. B.
    Han, C.
    Randazzo, B.
    Wasfi, Y.
    Shen, Y. -K.
    Li, S.
    Griffiths, C. E. M.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2018, 32 (09) : 1515 - 1522
  • [5] Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies
    Armstrong, April W.
    Reich, Kristian
    Foley, Peter
    Han, Chenglong
    Song, Michael
    Shen, Yaung-Kaung
    You, Yin
    Papp, Kim A.
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2019, 20 (01) : 155 - 164
  • [6] Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies
    April W. Armstrong
    Kristian Reich
    Peter Foley
    Chenglong Han
    Michael Song
    Yaung-Kaung Shen
    Yin You
    Kim A. Papp
    American Journal of Clinical Dermatology, 2019, 20 : 155 - 164
  • [7] Patient-reported symptoms and signs in patients with moderate-severe plaque psoriasis treated with guselkumab or adalimumab: Results from VOYAGE 1, a phase III clinical trial
    Blauvelt, Andrew
    Papp, Kim
    Griffiths, Christopher E. M.
    Han, Chenglong
    Randazzo, Bruce
    Wasfi, Yasmine
    Li, Shu
    Kimball, Alexa B.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB191 - AB191
  • [8] Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2
    Reich, K.
    Gordon, K. B.
    Strober, B. E.
    Armstrong, A. W.
    Miller, M.
    Shen, Y. K.
    You, Y.
    Han, C.
    Yang, Y. W.
    Foley, P.
    Griffiths, C. E. M.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (06) : 1146 - 1159
  • [9] Sustained improvement in general health-related quality of life and work productivity in patients with moderate to severe psoriasis treated with guselkumab: 5-year data from clinical trial VOYAGE 2
    Reich, Kristian
    Gordon, Kenneth B.
    Foley, Peter
    Lomaga, Mark
    Han, Chenglong
    Miller, Megan
    You, Yin
    Radtke, Marc Alexander
    Wu, Jashin J.
    Armstrong, April W.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB174 - AB174
  • [10] Clinician-reported PASI versus patient-reported symptoms and signs in moderate to severe psoriasis patients: Voyage 1&2 clinical trials
    Gordon, K.
    Han, C.
    Li, S.
    You, Y.
    Song, M.
    Fakharzadeh, S.
    Crowley, J.
    Reich, K.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2019, 60 : 42 - 42
12345